Emzor Pharmaceutical lists N26.70bn bond for API plant
What's the deal? Emzor PharmaceuticalDealroom has a profile for this one. Try Dealroom → has listed a N26.70 billion (≈$19.8 million) five-year fixed-rate bond on FMDQ ExchangeDealroom has a profile for this one. Try Dealroom →. The Series 1 bond, priced at 19%, falls under a wider N40 billion issuance programme and is Emzor's second domestic bond.
Who's behind it? The vehicle raises capital for Emzor Pharmaceutical IndustriesDealroom has a profile for this one. Try Dealroom →, a wholly Nigerian drug and medical consumables manufacturer. Renaissance Securities (Nigeria)Dealroom has a profile for this one. Try Dealroom → acted as lead sponsor, with FirstCapDealroom has a profile for this one. Try Dealroom → and UCML CapitalDealroom has a profile for this one. Try Dealroom → as co-sponsors.
What's the endgame? Proceeds go toward working capital and expanding local manufacturing capacity. The headline project is completing what the company calls the first full-scale antimalarial Active Pharmaceutical Ingredient (API) plant in Africa.
Why it matters: Nigeria relies heavily on imported APIs. The plant aims to cut that dependence and push the country toward pharmaceutical self-sufficiency, a goal echoed across the continent.
Board chairman Emeka Okoli said the issuance marks "a significant milestone in the company's efforts to deepen local pharmaceutical manufacturing," adding that oversubscription reflects investor "confidence" in Emzor's fundamentals.
The signal: The listing shows Nigeria's debt capital markets increasingly funding long-term projects in the real economy. As Tumi Sekoni, group chief operating officer at FMDQ GroupDealroom has a profile for this one. Try Dealroom →, put it, the deal connects "a leading indigenous pharmaceutical manufacturer with long-term investor capital" — a template for financing local industry without foreign dependence.
Read more: BusinessDay
Image credit: Generated with Gemini
